No Data
No Data
No Data
No Data
No Data
Evaluating BeiGene: Insights From 6 Financial Analysts
In the last three months, 6 analysts have published ratings on BeiGene (NASDAQ:BGNE), offering a diverse range of perspectives from bullish to bearish.The following table provides a quick overview of
Benzinga14:01 ET
BeiGene Is Maintained at Buy by TD Cowen
BeiGene Is Maintained at Buy by TD Cowen
Dow Jones13:35 ET
Express News | TD Cowen Maintains Buy on BeiGene, Raises Price Target to $236
Moomoo 24/713:26 ET
BeiGene Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/24/2024 64.52% TD Cowen $235 → $236 Maintains Buy 04/08/2024 14.53% B of A Securities $179.3 → $164.3 M
Benzinga13:24 ET
Express News | BeiGene Shares Are Trading Higher After the European Commission on Tuesday Approved Tislelizumab for Non-small Cell Lung Cancer Across Three Indications, Including First- and Second-line Use
Moomoo 24/7Apr 24 10:41 ET
Sector Update: Health Care Stocks Rise in Afternoon Trading
Health care stocks were advancing Tuesday afternoon, with the NYSE Health Care Index gaining 1.4% and the Health Care Select Sector SPDR Fund (XLV) up 1.3%. The iShares Biotechnology ETF (IBB) rose 1.
MT NewswiresApr 23 13:51 ET
No Data
No Data
SpyderCall : Very valuable info as usual. Thanks for the hard work.
shintaka1168 : こんな情報を配信してくれるなんて、おどろきました。これからもチェックしようと思います